MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, CLDX had $12,993K increase in cash & cash equivalents over the period. -$49,068K in free cash flow.

Cash Flow Overview

Change in Cash
$12,993K
Free Cash flow
-$49,068K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-67,044 -110,396
Depreciation and amortization
824 1,740
Amortization and premium of marketable securities, net
1,018 3,955
Loss on sale or disposal of assets
-6 -6
Stock-based compensation expense
8,801 18,507
Accounts and other receivables
0 -610
Prepaid and other current assets
2,785 -3,020
Other assets
64 -447
Accounts payable and accrued expenses
13,062 -6,632
Other liabilities
-410 -1,724
Net cash used in operating activities
-48,628 -98,377
Sales and maturities of marketable securities
116,915 367,873
Purchases of marketable securities
55,628 274,080
Acquisition of property and equipment
440 993
Net cash provided by (used in) investing activities
60,847 92,800
Proceeds from issuance of stock from employee benefit plans
774 265
Net cash provided by financing activities
774 265
Net increase in cash and cash equivalents
12,993 -5,312
Cash and cash equivalents at beginning of period
28,356 -
Cash and cash equivalents at end of period
36,037 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics, Inc. (CLDX)